LON:DPH

Dechra Pharmaceuticals - DPH Share Forecast, Price & News

GBX 2,808.54

+88.54 (+3.26%)

(As of 12/1/2022 05:03 PM ET)

Add

Compare

Today's Range: 2,770
▼
2,832
50-Day Range: 2,524
▼
2,968
52-Week Range: 2,487.45
▼
5,395

Volume: 238,380 shs
Average Volume: 331,784 shs
Market Capitalization: £3.20 billion

P/E Ratio: 5,299.13
Dividend Yield: 1.68%
Price Target: GBX 4,142.50

Dechra Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 47.5% Upside
GBX 4,142.50 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
£5.38 M Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
Dechra Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 4,142.50, Dechra Pharmaceuticals has a forecasted upside of 47.5% from its current price of GBX 2,808.54.
Amount of Analyst Coverage
Dechra Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for DPH.

0.8

Dividend Strength

Dividend Yield
Dechra Pharmaceuticals pays a meaningful dividend of 1.68%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Dechra Pharmaceuticals does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Dechra Pharmaceuticals is 78.09%. Payout ratios above 75% are not desirable because they may not be sustainable.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DPH.

1.1

News and Social Media Coverage

Search Interest
2 people have searched for DPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
1 people have added Dechra Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dechra Pharmaceuticals insiders have sold 78.64% more of their company's stock than they have bought. Specifically, they have bought £30,138.30 in company stock and sold £53,840.16 in company stock.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Dechra Pharmaceuticals is 5,299.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 123.91.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dechra Pharmaceuticals is 5,299.13, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 110.91.
Price to Earnings Growth Ratio
Dechra Pharmaceuticals has a PEG Ratio of 1.45. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Dechra Pharmaceuticals has a P/B Ratio of 4.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Dechra Pharmaceuticals (LON:DPH) Stock

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Receive DPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DPH Stock News Headlines

October 21, 2022 | finance.yahoo.com

Are Dechra Pharmaceuticals PLC's (LON:DPH) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

October 14, 2022 | bizjournals.com

M&A case study: Piedmont Animal Health sells to London-based company Dechra to commercialize products

October 7, 2022 | finance.yahoo.com

Quite a few insiders invested in Dechra Pharmaceuticals PLC (LON:DPH) last year which is positive news for shareholders

September 22, 2022 | finance.yahoo.com

Dechra Pharmaceuticals (LON:DPH) Has Announced That It Will Be Increasing Its Dividend To £0.3289

September 8, 2022 | finance.yahoo.com

Dechra Pharmaceuticals' (LON:DPH) Shareholders Will Receive A Bigger Dividend Than Last Year

September 5, 2022 | finance.yahoo.com

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

August 16, 2022 | finance.yahoo.com

What Is The Ownership Structure Like For Dechra Pharmaceuticals PLC (LON:DPH)?

August 2, 2022 | finance.yahoo.com

Dechra Pharmaceuticals' (LON:DPH) five-year earnings growth trails the stellar shareholder returns

August 1, 2022 | bizjournals.com

Piedmont Animal Health sold to UK company Dechra Pharmaceuticals for $210 million in cash

July 11, 2022 | nasdaq.com

Dechra Pharma FY22 Revenues Climb - Quick Facts

June 28, 2022 | uk.finance.yahoo.com

Are analysts upbeat on the outlook for Dechra Pharmaceuticals?

June 27, 2022 | finance.yahoo.com

Estimating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

June 7, 2022 | uk.finance.yahoo.com

How has the Dechra Pharmaceuticals share price performed over the past year?

May 29, 2022 | fool.co.uk

Dechra Pharmaceuticals

May 17, 2022 | uk.finance.yahoo.com

Is there momentum behind the Dechra Pharmaceuticals share price?

March 27, 2022 | finance.yahoo.com

With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting

March 7, 2022 | uk.finance.yahoo.com

2 FTSE 100 shares I’d buy as stocks fall

February 24, 2022 | finance.yahoo.com

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

February 23, 2022 | finance.yahoo.com

Dechra Pharmaceuticals' (LON:DPH) investors will be pleased with their splendid 152% return over the last five years

January 28, 2022 | uk.finance.yahoo.com

2 FTSE 100 growth stocks to buy right now

January 18, 2022 | finance.yahoo.com

Dechra Pharmaceuticals PLC (LON:DPH) Shares Could Be 31% Above Their Intrinsic Value Estimate

January 13, 2022 | markets.businessinsider.com

Dechra Pharma HY Revenue Up 15% At CER - Quick Facts

January 11, 2022 | nasdaq.com

Dechra Pharma To Buy Worldwide Rights To Verdinexor For Dogs

December 22, 2021 | fool.co.uk

Dechra Pharmaceuticals (LSE:DPH)

December 4, 2021 | finance.yahoo.com

Is Dechra Pharmaceuticals PLC's (LON:DPH) Stock Price Struggling As A Result Of Its Mixed Financials?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive DPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DPH Company Calendar

Ex-Dividend for 11/18 Dividend: 10/27/2022
Dividend Payable: 11/18/2022
Today: 12/01/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Drug Manufacturers - Major
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:DPH
CUSIP: N/A
CIK: N/A
Web: www.dechra.com
Phone: +44-1606-814730
Fax: N/A
Employees: 1,699
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: GBX 4,142.50
High Stock Price Forecast: GBX 5,700
Low Stock Price Forecast: GBX 2,850
Forecasted Upside/Downside: +47.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 5,299.13
Forward P/E Ratio: 21.02
P/E Growth: 1.45
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 49.36
Current Ratio: 2.80
Quick Ratio: 1.66

Sales & Book Value

Annual Sales: £681.80 million
Price / Sales: 4.69
Cash Flow: GBX 114.04 per share
Price / Cash Flow: 24.63
Book Value: GBX 615.20 per share
Price / Book: 4.57

Miscellaneous

Outstanding Shares: 113,825,000
Free Float: N/A
Market Cap: £3.20 billion
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Ian D. Page (Age 61)
CEO, MD & Exec. Director
Comp: $1.26M

Mr. Paul Nicholas Sandland MAAT (Age 43)
FCCA, CFO & Exec. Director
Comp: $790k

Dr. Anthony Gerard Griffin (Age 59)
MD of Dechra Veterinary Products for Europe & Exec. Director
Comp: $601k

Mr. Patrick Meeus
Group Scientific Officer

Ms. Katy Clough
Group HR Director

Mr. Mike Eldred (Age 52)
Pres of North America

Ms. Melanie Hall
Company Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DPH Stock - Frequently Asked Questions

Should I buy or sell Dechra Pharmaceuticals stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DPH shares.
View DPH analyst ratings or view top-rated stocks.
What is Dechra Pharmaceuticals' stock price forecast for 2023?: 4 equities research analysts have issued 1 year price objectives for Dechra Pharmaceuticals' stock. Their DPH share price forecasts range from GBX 2,850 to GBX 5,700. On average, they expect the company's share price to reach GBX 4,142.50 in the next year. This suggests a possible upside of 47.5% from the stock's current price.
View analysts price targets for DPH or view top-rated stocks among Wall Street analysts.
How have DPH shares performed in 2022?: Dechra Pharmaceuticals' stock was trading at GBX 5,325 at the beginning of the year. Since then, DPH stock has decreased by 47.3% and is now trading at GBX 2,808.54.
View the best growth stocks for 2022 here.
How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?: Dechra Pharmaceuticals declared a dividend on Monday, September 5th. Stockholders of record on Thursday, October 27th will be paid a dividend of GBX 32.89 per share on Friday, November 18th. This represents a yield of 0.99%. The ex-dividend date of this dividend is Thursday, October 27th. This is a boost from the stock's previous dividend of GBX 12. The official announcement can be viewed at this link.
Read our dividend analysis for DPH.
Is Dechra Pharmaceuticals a good dividend stock?: Dechra Pharmaceuticals (LON:DPH) pays an annual dividend of GBX 0.41 per share and currently has a dividend yield of 1.68%. The dividend payout ratio is 78.09%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for DPH.

What other stocks do shareholders of Dechra Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include 32Red (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SEB (SKP) and Barratt Developments (BDEV).
What is Dechra Pharmaceuticals' stock symbol?: Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."
How do I buy shares of Dechra Pharmaceuticals?: Shares of DPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Dechra Pharmaceuticals' stock price today?: One share of DPH stock can currently be purchased for approximately GBX 2,808.54.
How much money does Dechra Pharmaceuticals make?: Dechra Pharmaceuticals (LON:DPH) has a market capitalization of £3.20 billion and generates £681.80 million in revenue each year.
How many employees does Dechra Pharmaceuticals have?: The company employs 1,699 workers across the globe.
How can I contact Dechra Pharmaceuticals?: Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The official website for the company is www.dechra.com. The company can be reached via phone at +44-1606-814730.

This page (LON:DPH) was last updated on 12/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dechra Pharmaceuticals - DPH Share Forecast, Price & News

Dechra Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Dechra Pharmaceuticals (LON:DPH) Stock

DPH Stock News Headlines

DPH Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

DPH Stock - Frequently Asked Questions

Overall MarketRank^™